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In Brief
DNMT3B is frequently overexpressed in
melanoma, but it remains unclear how
DNMT3B modulates melanoma growth.
Micevic et al. report that loss of DNMT3B
in a mouse model of melanoma delays
tumor formation by altering mTORC2
signaling in melanoma cells. Their results
suggest DNMT3B as a therapeutic target
in melanoma.
Cell Reports
ArticleDNMT3b Modulates Melanoma Growth by Controlling
Levels of mTORC2 Component RICTOR
Goran Micevic,1,3,5 Viswanathan Muthusamy,1,2,5 William Damsky,1 Nicholas Theodosakis,1,3 Xiaoni Liu,3 Katrina Meeth,3
Emily Wingrove,3 Manjula Santhanakrishnan,1,4 and Marcus Bosenberg1,3,*
1Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
2Department of Chemistry, Yale University, New Haven, CT 06510, USA
3Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
4Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
5Co-first author
*Correspondence: marcus.bosenberg@yale.edu
http://dx.doi.org/10.1016/j.celrep.2016.02.010
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
DNA methyltransferase DNMT3B is frequently over-
expressed in tumor cells and plays important roles
during the formation and progression of several can-
cer types. However, the specific signaling pathways
controlled by DNMT3B in cancers, including mela-
noma, are poorly understood. Here, we report that
DNMT3B plays a pro-tumorigenic role in human
melanoma and that DNMT3B loss dramatically sup-
presses melanoma formation in the Braf/Ptenmouse
melanoma model. Loss of DNMT3B results in hypo-
methylation of themiR-196b promoter and increased
miR-196b expression, which directly targets the
mTORC2 component Rictor. Loss of RICTOR in
turn prevents mTORC2 activation, which is critical
for melanoma formation and growth. These findings
establish Dnmt3b as a regulator of melanoma forma-
tion through its effect on mTORC2 signaling. Based
on these results, DNMT3B is a potential therapeutic
target in melanoma.INTRODUCTION
Malignant melanoma is the deadliest form of skin cancer, with an
estimated 76,100 new cases and 9,710 deaths in the United
States in 2014 alone (Siegel et al., 2014). Despite recent ad-
vances in targeted therapy (Flaherty et al., 2012) and immuno-
therapies (Wolchok et al., 2013), the prognosis for melanoma
continues to be poor, underscoring the need for better under-
standing of the disease process and the development of novel
therapies (Korman and Fisher, 2013). Genomic studies have
helped define the somatic driver mutation landscape in mela-
nomawithBRAFmutations occurring in50%,NRASmutations
in 25%, and NF1 mutations in 10% of tumors (Cancer
Genome Atlas, 2015).
Epigenetic changes, including aberrant DNA methylation
(Schinke et al., 2010) and hydroxymethylation (Lian et al.,
2012), have emerged as important features of melanoma, but2180 Cell Reports 14, 2180–2192, March 8, 2016 ª2016 The Authorsthe functional effects of these changes are relatively poorly un-
derstood. DNA methylation plays a significant role in the devel-
opment and progression of many cancers (Baylin, 2005), and
epigenetic silencing due to aberrant promoter hypermethylation
may be responsible for more tumor-suppressor gene inactiva-
tion than genetic mutations (Jones and Baylin, 2007). Aberrant
DNA methylation of specific genes occurs nearly universally in
human melanoma (Koga et al., 2009; Muthusamy et al., 2006),
but the functional consequences of methylation and role of indi-
vidual methyltransferases in melanoma development are poorly
understood. DNA methylation in mammals is established by the
de novo DNMTs, DNMT3A and DNMT3B, whereas maintenance
of hemi-methylated loci is traditionally thought to bemediated by
DNMT1 (Wu and Zhang, 2014). Recently, detailed studies on the
division of labor among methyltransferases have revealed in-
stances of redundant function, as well as isoform-specific and
even antagonistic functions among these enzymes (Tiedemann
et al., 2014), underlying the need to differentiate their individual
contributions to the cancer epigenome and cancer progression.
DNMT3B is a de novo methyltransferase essential for
mammalian development (Okano et al., 1999) that has been
implicated in the initiation and progression of several tumor
types. Expression of DNMT3B is increased in many malig-
nancies, including hepatocellular (Saito et al., 2001), breast (Gir-
ault et al., 2003), oral (Yakushiji et al., 2003), and lung cancer
(Gao et al., 2011). In these tumor types, DNMT3B is thought to
affect tumor initiation and progression (Gopalakrishnan et al.,
2009; Kleinman et al., 2014; Ostler et al., 2007; Weisenberger
et al., 2004) and in some cases contribute to the widespread
CpG island promoter methylation seen in certain tumors, also
known as the methylator phenotype (Nosho et al., 2009; Roll
et al., 2008). It has been shown to target and silence tumor sup-
pressors in human cancers (Rhee et al., 2002) and promote
tumorigenesis of colon cancer in vivo (Linhart et al., 2007).
Loss of Dnmt3b also suppresses macroscopic colonic adenoma
formation in ApcMin/+ mice (Lin et al., 2006). Recently, it was
demonstrated that DNMT3B, but not other methyltransferases,
is required for re-methylation of gene bodies and may be a ther-
apeutic target with the potential to prevent rebound methylation
in cancer (Yang et al., 2014). Despite a clear role for DNMT3B in a
wide variety of human cancers, the signaling pathways that drive
cancer formation that are critically affected by DNMT3B are
largely unknown.
The role of DNMT3B in melanoma also remains poorly under-
stood. DNMT3B expression increases with melanoma progres-
sion (Nguyen et al., 2011), and DNMT3B has been associated
with p16INK4A methylation in melanoma (Venza et al., 2015).
However, it is unknown whether DNMT3B is required for mela-
noma formation. We have previously developed and character-
ized a genetically engineered mouse model of melanoma (Braf/
Pten model), which can be used to study the effect of Dnmt3b
loss in melanoma development. The Braf/Pten model is based
on Cre-lox-mediated melanocyte-specific conditional knockin
of oncogenic BrafV600E and knockout of the Pten tumor suppres-
sor. This model recapitulates a subset (15%–25%) of genetic/
signaling changes found in human melanoma (Birck et al.,
2000; Zhou et al., 2000). Upon induction of these genetic
changes, Braf/Pten mice develop melanoma with 100% pene-
trance without delay. In this study, we utilized the Braf/Pten
model to investigate the specific role of Dnmt3b in melanoma
formation and progression (Damsky et al., 2015; Dankort et al.,
2009). A panel of human melanoma cell lines and datasets
from The Cancer Genome Atlas were also used to examine the
role of DNMT3B in melanoma.
RESULTS
DNMT3B Expression Is Elevated in Human Melanoma,
Associated with Poor Survival, and Required for
Proliferation
We analyzedmRNA expression in a cohort of stage III melanoma
patients (n = 144; TCGA) to examine the relevance of DNMT gene
expression on 5-year overall survival. We found that high expres-
sion of DNMT3B, but not other DNMTs, was associated with
significantly shorter overall survival (Figure 1A). Expression
of DNMT3B did not vary significantly with ulceration, substage,
or Breslow thickness (Figure S1A; Table S1). Methylation of
CDKN2A was not significantly different between the high- and
low-expressing groups (Figure S1B). These findings are consis-
tent with a previous report associating high DNMT3B protein
with shorter overall survival in melanoma (Nguyen et al., 2011).
We next compared DNMT3B mRNA levels in human melanoma
cell lines to primary melanocytes in culture by qRT-PCR (Fig-
ure 1B) and found that DNMT3B is generally overexpressed in
melanoma relative to melanocytes. We did not find significant
differences in expression of DNMT3B between BRAF-driven
and NRAS-driven melanoma. Immunoblotting confirmed that
DNMT3B is overexpressed in melanoma cell lines relative to me-
lanocytes in culture (Figure 1C). Others have reported that PI3K
signaling can regulate DNMT3B levels in hepatocellular carci-
noma (Mei et al., 2010) and prostate cancer (Agarwal et al.,
2013). Similar to these results, we found that the PI3K inhibitor
BKM-120 caused a dose-dependent decrease in DNMT3B pro-
tein (Figure S1D), leading us to hypothesize that PI3K signaling
can also regulate DNMT3B inmelanoma. DysregulatedDNMT3B
expression is also associated with PTEN mutation in the TCGA
dataset. Specifically, in melanomas with high DNMT3B expres-
sion, PTENmutation frequency is 17%, compared to 7% in mel-
anomaswith lowDNMT3B expression (p = 0.02 by Fisher’s exactCetest). We did not detect a significant difference in miR-29 or SP1
(known regulators of DNMT3B) levels between melanocytes and
melanoma (Figures S1I and S1J).
We then asked whether DNMT3B confers a growth advantage
to human melanoma cells, as previously described in other can-
cer types (Beaulieu et al., 2002). We knocked down DNMT3B in
human melanoma lines using siRNA (Figure 1D) and observed a
significant decrease in proliferation upon DNMT3B depletion,
relative to a control pool (Figure 1E). To minimize the possibility
of off-target effects, we also used an unrelated siRNA targeting
DNMT3B (Figure S1C) and observed a similar decrease in
cell proliferation (Figure 1E). Notably, knockdown of DNMT3B
did not induce apoptosis-associated annexin V (Figure S1E) or
senescence-associated b-galactosidase staining (Figure S1F).
Together, these results suggest a tumor-promoting role for
DNMT3B in human melanoma.
To gain insight into the apparent pro-tumorigenic function
of DNMT3B, we compared the transcriptome of high- versus
low-DNMT3B-expressing human melanoma samples in TCGA
(Figure S1G). In the high-DNMT3B-expressing group, we noted
that many miRNA target genes were differentially abundant
between groups, suggesting that DNMT3B may regulate, or is
co-regulated with, miRNA networks. The most-enriched hits
(Table S2), miR-29 and let-7, have already been described as a
regulator (Fabbri et al., 2007) and target of DNMT3B (Hayashi
et al., 2013), respectively. Other miRs we identified, including
miR-196b (Table S2), have not been previously associated with
DNMT3B.
DNMT3B Loss Markedly Suppresses Melanoma
Formation In Vivo
To investigate the role of Dnmt3b in melanoma formation in vivo,
we evaluated the effects of Dnmt3b loss in the Braf/Pten model
using a previously described Dnmt3blox allele (Lin et al., 2006).
We first assessed the effect of Dnmt3b loss on normal murine
melanocyte viability and proliferation on a mixed C57BL6/FVB/
129S4 background. Immunohistochemical staining for SOX10,
a robust marker of melanocytes in hair follicles, demonstrated
the presence of bulb melanocytes in all visualized hair follicles
at normal frequencies, despite Dnmt3b loss (Figures S2A and
S2B). Notably, there was no decrease in the density of junctional
melanocytes in tail skin or increase in gray or white hair associ-
ated with Dnmt3b loss throughout the life of the animal (Fig-
ure S2D). This approach (monitoring graying and presence of
follicular melanocytes) has previously been demonstrated to reli-
ably identify genes required for melanocytic viability (Levy et al.,
2010). Thus, homozygous Dnmt3b loss did not result in death of
melanocytes in tissue. Furthermore, knockdown of DNMT3B in
murine melanocytes in vitro did not affect proliferation of mela-
nocytes (Figures S2C and S2E), did not lead to increased
apoptosis-associated annexin V staining (Figure S2F), and did
not induce senescence-associated b-galactosidase activity
(Figure S2G). These findings suggest that Dnmt3b does not
play prominent roles in melanocyte survival and proliferation,
consistent with low expression of DNMT3B in most benign so-
matic tissues (Chen et al., 2003).
We proceeded to investigate the effect of Dnmt3b loss
on melanoma formation in the Braf/Pten mouse model on all Reports 14, 2180–2192, March 8, 2016 ª2016 The Authors 2181
Figure 1. DNMT3B Plays a Pro-tumorigenic Role in Melanoma
(A) Survival analysis of melanoma patients (TCGA) stratified by expression ofDNMT3B (left),DNMT1 (middle), orDNMT3A (right). Cohort was split into high versus
low DNMT expression at the 75th percentile. Log rank test; *p < 0.05; NS p > 0.05. See also Figures S1A and S1B and Table S1.
(B) Quantification of DNMT3B expression in melanocytes and a panel of human melanoma lines with driver mutations in Braf, Nras, or no known driver
mutations (‘‘WT’’).
(C) Western blot analysis of DNMT3B expression in melanocytes and a panel of human melanoma cell lines. See also Figure S1H.
(D)Western blot analysis of DNMT3B knockdown in humanmelanoma lines YUGEN, YUMUT, andWM46 transfectedwith DNMT3B knockdown pool (siDNMT3B)
or control (siCtrl).
(E) Knockdown of DNMT3B significantly reduced proliferation of human melanoma in vitro compared to control in YUGEN, YUMUT, and WM46 melanoma lines.
RLU, relative luminescence units (n = 4 per condition). See also Figure S1C.
Data in (B) and (E) are presented as mean ± SEM; Student’s t test; **p < 0.01; ***p < 0.001. See also Figure S1 and Tables S1 and S2.mixed C57BL6/FVB/129S4 background. In brief, in the Braf/
Pten model, localized induction of Cre-mediated recombination
results in BrafV600E expression and Pten inactivation in cuta-
neous melanocytes, new melanocytic tumors are visible within
10 days, and 1 cm3 tumors form in all mice within 70 days (Dan-
kort et al., 2009). Loss of Dnmt3b in this model resulted in a strik-2182 Cell Reports 14, 2180–2192, March 8, 2016 ª2016 The Authorsing delay in melanoma formation compared to Dnmt3bWT Braf/
Pten mice (Figures 2A, 2B, and S3A). Tumor-specific median
survival (tumor burden of 1 cm3) was increased over 5-fold in
the Dnmt3blox/lox cohort compared to the Dnmt3bWT cohort
(234 versus 42 days), with some animals surviving longer than
a year. Recombination of the Braf, Pten, and Dnmt3blox alleles
Figure 2. DNMT3B Loss Delays Tumor Formation in a Mouse Model of Melanoma
(A) Dnmt3blox/lox Braf/Pten mice (blue line) exhibited significantly increased tumor-specific survival and delayed melanoma formation relative to Dnmt3bwt Braf/
Pten mice (red line; n = 17 for Dnmt3blox/lox; n = 13 for Dnmt3bwt; log rank test; p < 0.0001). The increase in median survival with Dnmt3b loss is approximately
5-fold (243 days versus 42 days post-induction). See also Figure S3A. All mice are on a mixed C57BL/6/FVB/129S4 background.
(B) Representative gross appearance of a Dnmt3bwt (left) and Dnmt3blox/lox (right) mouse at 20 days post-induction. The scale bar represents 1 cm.
(C) Recombination-specific PCR measuring percent recombination of Dnmt3blox alleles in Dnmt3blox/lox tumors.
(D) Western blot analysis of DNMT3B expression in Braf/Pten melanoma (left) and murine melanocytes (right) derived from littermate controls as described in
Supplemental Experimental Procedures. Two biological replicates are shown per group, representative of three independent experiments. See also Figure S3C.
(E) Western blot analysis of DNMT3B expression in Dnmt3bwt Braf/Pten tumors (left) and Dnmt3blox/lox Braf/Pten tumors (right) derived from cohort in (A). Two
biological replicates are shown per group.
(F) qPCR analysis of Dnmt3b expression in Dnmt3blox/lox and Dnmt3bwt Braf/Pten tumors (n = 3 per genotype). Primer sequences are listed in Supplemental
Experimental Procedures.
(G) H&E-stained tumor from Dnmt3blox/lox Braf/Ptenmouse. The presence of abundant melanin pigment (arrowheads) within tumor cells at the dermal/epidermal
junction and within the dermis is diagnostic of melanoma. See also Figures S3D and S3E. The scale bar represents 100 mm.
(H) Lymph node metastasis quantification in the Dnmt3bwt and Dnmt3blox/lox cohort. Data are presented as percent area of lymph node involved (n = 10 for
Dnmt3bwt; n = 6 for Dnmt3blox/lox).
(I) Pyknotic and mitotic index quantification in the Dnmt3bwt and Dnmt3blox/lox cohort. Data are presented as mean number of pyknotic cells or mitotic figures
per mm2 (pyknotic index: n = 13 per group; mitotic index: n = 12 per group).
Data in (F), (H), and (I) are presented asmean ± SEM. Statistical significance: NS p > 0.05; *p < 0.05; **p < 0.01; and ***p < 0.001 by two-sided Student’s t test. See
also Figures S2 and S3.
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Figure 3. DNMT3B Loss Results in a Nevic Arrest Phenotype
(A) Representative stereomicroscope light images of dissected, internal aspect of skin 12 days after induction in Braf (left), Dnmt3bwt Braf/Pten (center), and
Dnmt3blox/lox Braf/Pten (right) mice. Melanocytic proliferations inBraf/Pten are heterogeneous in size and proliferation kinetics compared to the homogenous size
of Braf/Pten/Dnmt3b, which is similar to lesions seen in mice with only melanocyte-specific Braf activation. The scale bar represents 1 mm.
(legend continued on next page)
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was confirmed by recombination-specific PCR (Figures 2C and
S3B). Themajority of hair bulbmelanocytes undergo recombina-
tion using the CreERT2 allele, as previously described in detail
(Bosenberg et al., 2006; Harris and Pavan, 2013). Loss of
Dnmt3b expression was confirmed by qRT-PCR and western
blotting (Figures 2E and 2F). Similar to our findings in humanmel-
anoma, Dnmt3b protein was overexpressed inmurinemelanoma
cell lines relative to primary melanocytes by western blotting
(Figure 2D) and immunohistochemistry (IHC) (Figure S3C). The
histologic features of Dnmt3blox/lox tumors were similar to those
seen in the Braf/Pten model and included superficial melanin
pigmentation (Figure 2G), invasion of adjacent tissue structures
(Figure S3D), and growth as sheets of atypical spindled and
epithelioid cells (Figure S3E, left). A decrease in lymph node tu-
mor burden was exhibited byDnmt3blox/loxmice (Figure 2H). The
mitotic index of Dnmt3bWT tumors is 6-fold higher than in
Dnmt3blox/lox tumors (Figure 2I, right). Quantification of pyknotic
(apoptotic) cells revealed no significant difference between
Dnmt3bWT and Dnmt3blox/lox tumors (Figure 2I, left), consistent
with lack of induced apoptosis with DNMT3B loss in vitro (Fig-
ure S1E). No differences in p16INK4A and p19ARF expression
were noted (Figure S2G) withDnmt3b loss, consistent with no ef-
fect on CDKN2A methylation by DNMT3B mutations in TCGA
(Figure S1B).
Interestingly, 12 days after induction, Dnmt3blox/lox mice ex-
hibited small nevus-like melanocytic proliferations of uniform
size at the induction site (Figure 3A, right). These lesions resem-
bled growth-arrested nevi following Braf activation alone (Fig-
ure 3A, left) and were in contrast to the variably sized and often
relatively large melanocytic lesions seen in the Braf/Pten model
(Figure 3A, middle) at the same time point. Importantly, nevus
sizes remained essentially stable at 90 days after induction of
recombination in Dnmt3blox/lox mice (Figures 3B and 3C, right),
underscoring a dramatic inhibition of melanocyte proliferation.
This attenuated growth was consistent with decreased KI-67
staining (Figure 3D) and decreased mitotic index in Dnmt3blox/lox
lesions (Figure 2I). Loss of Dnmt3b resulted in a significant
decrease in the number of large (>0.25mm2)melanocytic prolifer-
ations (Figure 3E) compared toDnmt3bWT Braf/Ptenmice. These
findings suggest that the decrease growth of melanoma in
Dnmt3blox/lox tumors is primarily due to reduced proliferation rela-
tive to Dnmt3bWT tumors. Loss of Dnmt3b in Braf/Pten mice
resembled the phenotype seen with melanocytic Braf activation
alone, strongly suggesting that Dnmt3b loss was predominantly
suppressing themelanomagenic effects ofPten loss in thismodel
(Figure3F). Thisobservation ledus to investigatewhetherDnmt3b
loss affected PI3K signaling in melanoma.(B) Representative image of melanocytic proliferations in the skin of Dnmt3blox
represents 1 mm.
(C)H&E-stained nevi fromDnmt3bwtBraf/Pten (left panel) andDnmt3blox/lox Braf/Pt
model at day 12.Nevi inDnmt3blox/lox Braf/Ptenmiceare smaller, uniform in size, an
(D) Representative KI-67 immunohistochemical staining in Dnmt3bwt and Dnmt3
100 nuclei counted is shown (n = 9 per group). Arrowhead indicates KI-67-positi
(E) Quantification of large melanocytic proliferations (defined as >0.25 mm2) inDnm
condition).
(F) Schematic of signaling changes and phenotypes observed with Braf activa
activation and Pten loss (right).
Data in (D) and (E) are presented as mean ± SEM. Statistical significance: *p < 0.05
CeRICTOR Is Markedly Reduced in Dnmt3blox/lox Braf/Pten
Tumors
This similarity of the growth phenotypes following Braf activation
(alone) and the Dnmt3blox/lox Braf/Pten model suggested that
Dnmt3b loss may affect PI3K signaling. Modulation of PI3K
and downstream signaling effectors including AKT, mTORC1,
and/or mTORC2 can have marked effects on melanoma forma-
tion (Damsky et al., 2011, 2015; Karbowniczek et al., 2008; She
et al., 2010). To evaluate potential changes in PI3K or down-
stream mTOR signaling, western blots were performed using
protein lysates prepared from Dnmt3blox/lox and Dnmt3bWT
Braf/Ptenmelanoma tumors (Figures 4A and S4A). Interestingly,
the obligate mTORC2 component RICTOR was markedly
reduced in Dnmt3blox/lox tumors (Figure 4A). RICTOR is an
essential component of mTORC2 and the primary kinase that
phosphorylates pAKT(S473), a modification required for full acti-
vation of AKT (Guertin et al., 2006). We observed decreased
pAKT(S473) and decreased phosphorylation of the AKT sub-
strate PRAS40 (Figure 4A), consistent with diminished AKT activ-
ity upon DNMT3B loss. We did not observe changes in mTORC1
component RAPTOR but noted reduced pS6K(T389) (Fig-
ure S4A). A plausible explanation for this observation is that
reduced inhibitory phosphorylation of PRAS40 allows it to
more fully inhibit mTORC1 activity. Taken together, these results
suggest that DNMT3B loss results in decreased RICTOR expres-
sion and abrogates activation of mTORC2 signaling.
To investigate potential effects of mTORC1 inhibition on
RICTOR protein levels, we treated melanoma cells with rapamy-
cin, an mTORC1-specific inhibitor. Rapamycin treatment re-
sulted in decreased phosphorylation (activation) of S6K and
4EBP1, as expected (Figures 4B and S4H). Importantly, we did
not observe decreased RICTOR expression upon inhibition of
mTORC1 signaling with rapamycin (Figures 4B and S4H), sug-
gesting that alteration in mTORC1 activity is not directly respon-
sible for the decrease in Rictor protein observed with DNMT3B
loss. These findings are consistent with prior work showing
that inhibition of mTORC1 with rapamycin can result in paradox-
ical elevation of mTORC2 and AKT signaling secondary to dimin-
ished IRS-mediated feedback inhibition (Findlay et al., 2005).
To test the validity of these findings in human melanoma, we
knocked down DNMT3B in BRAF-driven human melanoma (Fig-
ures 4C and S4B) and NRAS-driven melanoma (Figure S4C) us-
ing siRNA. Reduction in DNMT3B resulted in decreased RICTOR
protein level, as well as a decrease in pAKT(S473), but no signif-
icant changes in RAPTOR level (Figure 4D, right). We compared
levels of pAKT(S473) in DNMT3B-mutated and DNMT3BWT
human melanoma samples in TCGA and found significantly/lox Braf/Pten mouse 90 days post induction of recombination. The scale bar
enmicedemonstrate largermelanocytic proliferations thanDnmt3bwtBraf/Pten
ddonot grow substantially even up today 90. The scale bar represents 100mm.
blox/lox tumors. Quantification of KI-67-positive nuclei percentage with at least
ve cells. The scale bar represents 100 mm.
t3bwt andDnmt3blox/loxBraf/Ptenmice per 25mm2 area (n = 6 area counts per
tion (left), Braf activation and Pten loss (middle), and Dnmt3b loss with Braf
; **p < 0.01; and ***p < 0.001 by two-sided Student’s t test. See also Figure S3.
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Figure 4. Inactivation of Dnmt3b Results in Loss of RICTOR
(A) Western blot analysis ofDnmt3bwt (left two lanes; days 35 and 42 post-induction) andDnmt3blox/lox Braf/Pten (right two lanes; day 100 and 200 post-induction)
tumor protein lysates. See (D) for quantification and Figure S4A. Data shown are representative of three independent experiments.
(B) Western blot analysis ofDnmt3bwt Braf/Ptenmelanoma cell line treatedwith rapamycin and/or knockdown of RICTOR. Data shown are representative of three
experiments. See also Figure S4H for quantification.
(C) Western blot analysis of signaling changes upon DNMT3B knockdown in two human melanoma cell lines (WM46 and YUGEN). See (D) and Figure S4B.
(D) Quantification of western blots from (left) (A) and (right) (C). Protein quantification is normalized to b-actin and representative of three independent experiments
(n = 3).
(legend continued on next page)
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decreased pAKT(S473) in mutated cases (Figure S4D), in agree-
ment with our experimental findings. Knockdown of RICTOR in
humanmelanoma lines (Figure S4E) significantly decreased pro-
liferation (Figure 4E), suggesting that RICTOR also plays impor-
tant roles in proliferation of human melanoma.
These results suggested to us that mTORC2 downregulation
could be a primary event contributing to diminished melanoma
formation in the setting of DNMT3B loss. To investigate this hy-
pothesis, we tested whether expression of RICTOR in the setting
of DNMT3B deficiency could rescue proliferation in vitro and
in vivo. We established murine and human melanoma cell lines
lacking DNMT3B. Murine lines were derived from Dnmt3blox/lox
Braf/Pten tumors, whereas DNMT3B gRNA and CRISPR/
hCAS9 was used (Figure S4F) to generate a human melanoma
line lacking DNMT3B (Figure S4G). Next, we overexpressed
RICTOR and selected for clones with stable expression, as
confirmed by immunoblotting (Figure S4G). DNMT3B-deficient
cell lines exhibited a diminished capacity for colony forma-
tion relative to DNMT3B-sufficient parental lines (Figure 4F).
Importantly, expression of RICTOR in DNMT3B-deficient lines
rescued colony formation capacity to DNMT3B wild-type levels
(Figure 4F).
Next, we subcutaneously injected parental (DNMT3B-suffi-
cient), DNMT3B-deficient, or DNMT3B-deficient + RICTOR-
overexpressing cell lines into flanks of nude mice and monitored
tumor growth. DNMT3B-deficient cell lines exhibited signifi-
cantly slower tumor growth compared to parental lines (Fig-
ure 4G). RICTOR expression rescued tumor growth rate to
parental line growth rates in vivo (Figure 4G). These findings
suggest that RITCOR is the predominant mediator of abrogated
proliferation in the setting of DNMT3B loss. We next sought to
determine the mechanism of RICTOR protein regulation by
DNMT3B.
Epigenetic Regulation of miR-196b by DNMT3B
Modulates Levels of RICTOR in Melanoma
To investigate themechanism(s) by which DNMT3B loss leads to
loss of Rictor, we quantified RictormRNA between Dnmt3blox/lox
and Dnmt3bWT Braf/Pten tumors. There was no statistically sig-
nificant difference in Rictor mRNA levels in Dnmt3blox/lox tumors
compared to Dnmt3bWT Braf/Pten tumors (Figure 5A), suggest-
ing that a post-transcriptional mechanism likely accounted for
RICTOR regulation by DNMT3B. We evaluated whether RICTOR
protein stability was regulated by DNMT3B levels by knocking
down DNMT3B in the presence and absence of cyclohexamide
but did not see significant changes in RICTOR protein stability
(Figure S5E). Based on these results and our previous observa-
tion that miRNA-regulated genes are among the most-enriched(E) RICTOR knockdown significantly decreases proliferation of humanmelanoma c
melanoma proliferation (n = 3 replicates per condition). See also Figure S4E.
(F) Representative image of colony formation by Dnmt3bwt, Dnmt3blox/lox, and R
Quantification of colonies is shown (n = 3 wells per condition).
(G) Tumor growth of (top panel) xenografted human melanoma cell line YUKO
expression and (bottom panel) grafted murine melanoma cell line compared to Dn
cell line).
Data in (D), (E), (F), and (G) are presented asmean ± SEM. Statistical significance: N
See also Figure S4.
Cegene sets affected by DNMT3B expression (Figure S1G), we
evaluated possible miRNA regulation of RICTOR.
Rictor is known to be regulated by several families of miRNAs
(Oneyama et al., 2013; Venkataraman et al., 2013). We identified
differentially expressed miRNAs between Dnmt3blox/lox and
Dnmt3bWT Braf/Pten melanoma tumors (Figure S5A; Table S3)
and cross-referenced them with miRNAs predicted to target
Rictor in silico (Lewis et al., 2003; Figure 5B). This approach
yielded two potential candidates present in both groups: miR-
148 and miR-196b (Figure 5C). To examine the functional effect
of miR-196b and miR-148 on RICTOR protein, these miRNAs
were expressed in murine and human melanoma lines. miR-
196b expression resulted in decreased protein levels of RICTOR
(Figure 5D), whereas miR-148 did not affect RICTOR levels (Fig-
ure S5B). In addition to decreasing RICTOR level, miR-196b
expression suppressed proliferation of human and murine
melanoma lines (Figure 5E). This anti-proliferative effect could
be rescued by exogenous expression of human RICTOR
lacking the miR-196b target sequence (Figure 5F). Notably, the
miR-196b target sequence in the 30 UTR of RICTOR is
100% conserved between Homo sapiens and Mus musculus
(Figure S5C).
Next, we investigated whether miR-196b attenuation could
functionally rescue the DNMT3B depletion-promoted prolifera-
tion defect. We co-silenced Dnmt3b and miR-196b and found
that proliferation of DNMT3B-deficient melanoma was restored
to Dnmt3bWT levels (Figure 5G). Gene set enrichment analysis
of differentially expressed genes between Dnmt3bWT and
Dnmt3blox/lox Braf/Pten melanoma demonstrated an enrichment
of miR-196b targets in the Dnmt3bWT phenotype (Figure S5D).
Together, these findings suggest an important role for miR-
196b in regulating mTORC2 component RICTOR and mediating
the phenotype observed upon Dnmt3b loss.
We next investigated the mechanism of increased miR-196b
expression in Dnmt3blox/lox relative to Dnmt3bWT melanoma.
qPCR analysis of miR-196b confirmed increased levels in
Dnmt3blox/lox compared to Dnmt3bWT Braf/Ptenmelanoma (Fig-
ure 6A). We asked whether DNA methylation is regulating miR-
196b expression by investigating the methylation status of the
miR-196b promoter CpG island using bisulfite sequencing. Our
results demonstrate that miR-196b is methylated in Dnmt3bWT
but hypomethylated in Dnmt3blox/lox tumors and melanocytes
(Figures 6B, S6A, S6B, and S6E). To further investigate these
findings, we knocked down DNMT3B in human melanoma lines
and analyzed the miR-196b promoter methylation status using
methylation-specific primers previously validated in human tis-
sues (Tsai et al., 2010). We found that DNMT3B knockdown re-
sulted in demethylation of the miR-196b promoter (Figure 6C)ell lines (WM46 and YUGEN), suggesting thatmTORC2 plays important roles in
ICTOR overexpressing Dnmt3blox/lox mouse and human cells. (Bottom panel)
LI, compared to DNMT3B-deficient YUKOLI, with or without RICTOR over-
mt3b deficiency with or without Rictor re-expression (n = 10 grafted tumors per
S p > 0.05; *p < 0.05; **p < 0.01; and ***p < 0.001 by two-sided Student’s t test.
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Figure 5. DNMT3B Regulates RICTOR by Targeting MicroRNA miR-196b
(A) qRT-PCR analysis of RictormRNA expression in Dnmt3blox/lox and Dnmt3bwt tumors. No statistically significant difference in mRNA level is shown (n = 3 per
group).
(B) Rank list of miRNAs predicted to target Rictor based on seed sequence. List was obtained using TargetScan and sorted based on PCT score.
(C) Venn diagram cross-referencing list of differentially expressedmiRNAs and list of predicted miRNA regulators of Rictor (B) identifies two candidate miRNAs—
miR-196b and miR-148. See also Figure S5A.
(D) Western blot analysis of RICTOR protein after miR-196b mimic transfection in Braf/Pten melanoma cell lines. Values below bands represent quantitative
densitometry readings, representative of three experiments.
(E) miR-196b mimic transfection decreased proliferation of Braf/Pten murine melanoma cells (2,697 and 2,901) and human melanoma (501mel) compared to
control transfected cells (n = 4 replicates).
(F) Ectopic expression of human RICTOR lacking miR-196b target sequence rescues proliferation of human melanoma cell line transfected with miR-196b mimic
(n = 3 replicates).
(G) miR-196b antagomir rescues proliferation defect induced byDNMT3B deficiency inBraf/Ptenmurinemelanoma cells (2,697 and 2,901) and humanmelanoma
(501mel; n = 3 replicates).
Data in (A), (E), (F), and (G) are presented asmean ±SEM. Statistical significance: NS p > 0.05; *p < 0.05; **p < 0.01; and ***p < 0.001 by two-sided Student’s t test.
See also Figure S5.
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Figure 6. miR-196bMethylation by DNMT3B
Plays an Important Role in Melanoma
(A) Quantitative Taqman miRNA assay demon-
strates increased abundance of miR-196b in
Dnmt3blox/lox relative to Dnmt3bwt Braf/Pten mel-
anoma (n = 3 per genotype).
(B) Bisulfite sequencing of miR-196b promoter in
Dnmt3bwt and Dnmt3blox/lox Braf/Pten tumors. Hy-
pomethylation of promoter is seen in Dnmt3blox/lox
relative to Dnmt3bwt tumors (n = 10 replicates;
Mann-Whitney U-test; ***p < 0.001).
(C) miR-196b-methylation-specific PCR product
agarose gel-electrophoresis. Knockdown of
DNMT3B leads to demethylation of miR-196b in
human melanoma lines.
(D) Taqman gene expression assay measuring
miR-196b levels upon knockdown of DNMT3B in
human melanoma lines (n = 3 per condition).
(E) Scatterplot of paired miR-196b methylation
and DNMT3B expression from the melanoma
TCGA cohort. Slope of linear regression curve is
significantly different from zero (Student’s t test;
p < 0.0001).
(F) Patient sub-group with low methylation of miR-
196b (n = 108) has higher 5-year overall survival
compared to sub-group with high miR-196b
methylation (n = 36; log rank test; *p < 0.05); cohort
was divided by miR-196b methylation level at
the 75th percentile into high methylation and low
methylation group. Full cohort information is
available in Table S1.
Data in (A) and (D) are presented as mean ± SEM.
Statistical significance: *p < 0.05; **p < 0.01; and
***p < 0.001 by two-sided Student’s t test. See
also Figure S6 and Tables S1 and S4.and increasedmiR-196b expression (Figure 6D). Together, these
results suggest that loss of DNMT3B results in hypomethylation
and elevated expression of miR-196b, which in turn represses
RICTOR expression.
To investigate whether DNMT3B expression and miR-196b
methylation were associated in clinical specimens, we analyzed
methylation patterns in stage III melanoma patients from the
TCGA dataset. We found that high DNMT3B expression is asso-
ciated with increased methylation of miR-196b (Figures 6E and
S6C), consistent with expression changes of miR-196b target
genes (Figure S1G). To investigate whether this phenomenon
might be present in other tumor types, we also analyzed miR-
196b methylation and DNMT3B expression in the hepatocellular
carcinoma (HCC) TCGA dataset and found a similar positive as-
sociation (Figure S6D). Interestingly, high methylation of miR-
196b in melanoma is associated with poor survival (Figure 6F)
and miR-196b methylation is an independent predictor of overall
survival in the entire melanoma patient cohort by Cox-propor-
tional hazard multivariable testing (Table S4).
Collectively, our results shed light on a specific signaling
pathway regulated by DNMT3B in melanoma and suggest that
mTORC2 regulation by DNMT3B plays important roles in mela-
noma proliferation.CeDISCUSSION
Aberrant DNA methylation is nearly universal in human mela-
noma (Koga et al., 2009; Muthusamy et al., 2006), but the
functional consequences of methylation and role of individual
DNMTs in melanoma development are poorly understood. The
de novo methyltransferase DNMT3B has been implicated in
the initiation and progression of many tumors, has been reported
to contribute to focal DNA hypermethylation, and in some cases
is required for cancer cell survival (Nosho et al., 2009; Roll et al.,
2008). Elevated levels of DNMT3B have been shown to correlate
with poor prognosis in a many cancer types (Chen et al., 2014;
Girault et al., 2003; Hayette et al., 2012). However, despite robust
evidence implicating DNMT3B in the process of tumorigenesis
and proliferation, signaling pathways modulated by DNMT3B
in cancer have not been well established experimentally. Here,
we present evidence from a genetically engineered mouse
model of melanoma and human melanoma cell lines that
DNMT3Bmodulates mTORC2 activity via miR-196b methylation
and plays an important role in melanoma formation (Figure 7).
Using the TCGA dataset and a panel of human melanoma cell
lines, we found that DNMT3B is overexpressed in melanoma
relative to melanocytes, high expression was associated withll Reports 14, 2180–2192, March 8, 2016 ª2016 The Authors 2189
Figure 7. DNMT3B Regulates Melanoma Formation via miR-196b
and mTORC2 Signaling
(A) DNMT3B suppresses miR-196b-mediated inhibition of RICTOR, allowing
full mTORC2 activation and melanoma formation with no latency.
(B) Loss of DNMT3B results in elevation ofmiR-196b levels and loss of RICTOR
expression, preventing mTORC2 activation and markedly delaying melanoma
formation.poorer survival, and DNMT3B is required for optimal proliferation
in vitro. Loss of Dnmt3b in the Braf/Pten mouse model sup-
pressed melanoma formation to the greatest extent observed
in this model to date and mimicked the benign melanocytic
nevus-like proliferations seen with Braf activation alone (Dankort
et al., 2009). This phenotypic observation suggests that Dnmt3b
loss attenuates the activation of the PI3K/mTOR pathways
downstream ofPten. Beyond this, the striking delay inmelanoma
formation suggests that other DNMTs do not adequately
compensate for Dnmt3b loss, suggesting isoform specific,
non-redundant roles for DNMTs in melanoma. Consistent with
this idea is a recent study suggesting a division of labor among
methyltransferases (Tiedemann et al., 2014) and that DNMT3B
in particular may play specific, non-redundant roles (Baubec
et al., 2015).
Analysis of tumors with genetic loss of Dnmt3b revealed a
decrease of RICTOR and pAKTS473, which are required for full
activation of the PI3K/AKT pathway. We obtained analogous
results upon DNMT3B knockdown in BRAF- and NRAS-driven
human melanoma lines. Notably, DNMT3B-deficiency-induced
proliferation attenuation could be rescued by RICTOR overex-
pression in vitro and in vivo. We identified that miR-196b can
decrease RICTOR protein level and melanoma proliferation,
which can be rescued by ectopic RICTOR expression. The miR-
196b promoter was hypomethylated upon DNMT3B loss, which
was also associated with increased expression of miR-196b.
In summary, mTORC2 signaling appears to be critical for mel-
anoma formation, and here, we show that DNMT3B plays a sig-
nificant role regulating this pathway by methylating miR-196b in
melanoma. In silico analysis of HCC samples also revealed a
positive link between DNMT3B expression and miR-196b
methylation. Given that DNMT3B is necessary for proliferation
of many cancer types (Beaulieu et al., 2002), the signaling axis
we describe herein linking DNMT3B to mTORC2 may play a2190 Cell Reports 14, 2180–2192, March 8, 2016 ª2016 The Authorsrole in other cancer types. Whereas PI3K/Akt activation plays
well-known roles in melanoma growth and AKT is a well-defined
target of mTORC2, other mTORC2 targets, including SGKs and
PKCa, merit future investigation. Along these lines, SGK3 and
SGK1 were recently shown to regulate melanoma proliferation
(Scortegagna et al., 2015).
The reversible nature of DNAmethylation is an attractive target
for therapy. FDA-approved demethylating agents are used for
treatment of myelodysplastic syndrome and AML as well as in
clinical trials for combination therapy of solid tumors (Li et al.,
2013). There is also evidence that DNMT3B inhibition sensitizes
tumor cells to conventional chemotherapy (Sandhu et al., 2012).
However, the currently available pan-DNMT inhibitors are non-
specific and have a poorly understood mode of action (Shen
and Laird, 2012) and a narrow therapeutic index. Our results,
taken together with studies suggesting a specific role for
DNMT3B in gene body methylation (Baubec et al., 2015) and
the requirement of DNMT3B in re-methylation in cancer (Yang
et al., 2014), suggest that DNMT3B plays important, non-redun-
dant roles in carcinogenesis and merits development of direct
and specific inhibitors.
EXPERIMENTAL PROCEDURES
Mouse Strains and Melanoma Cell Lines
The Tyr-CreERT2, BrafCA, Ptenlox, and Dnmt3blox alleles have been described
previously (Dankort et al., 2009; Lin et al., 2006) and were genotyped and
assayed for recombination using PCR. All mice were maintained on a
mixed C57BL/6/FVB/129S4 background. All experiments were reviewed and
approved by the Yale IACUC.
Western Blotting, Transfection Experiments, and Proliferation
Assays
Western blotting, transfection, and proliferation assays were performed using
standard methods described previously (Damsky et al., 2015). Antibody list
and catalog numbers for siRNAs, miRNAs, and plasmids are provided in
Supplemental Experimental Procedures.
Bisulfite Modification, Sequencing, and qPCR
Genomic DNA was bisulfite modified following EpiTect (QIAGEN) kit 1 mg pro-
tocol. PCR products were cloned using the TOPO TA cloning Kit (Invitrogen),
according to manufacturer’s instructions, and Sanger sequenced (GeneWiz).
qPCR was performed using FirstStrand cDNA Synthesis kit (Roche) and
SYBR Green (Roche) or miRNA Taqman assays (ThermoFisher), following
manufacturer’s instructions. All primer sequences are provided in Supple-
mental Experimental Procedures.
Statistical Analyses
Statistical analyses were performed using paired and unpaired two-tailed
Student’s t test, Mann-Whitney U-test, and log rank (Mantel-Cox) test in
GraphPad Prism using a significance cutoff; *p < 0.05. GSEA was performed
using publicly available software from the Broad Institute.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.02.010.
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